中国肺癌杂志2024，Vol.27Issue(2)：138-146,9.DOI:10.3779/j.issn.1009-3419.2024.102.06
可切除非小细胞肺癌新辅助免疫治疗研究进展
Progress on Neoadjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer
摘要
Abstract
In recent years,there has been a consensus regarding the enhancement of prognosis in patients with ad-vanced non-small cell lung cancer(NSCLC)through the utilization of immune checkpoint inhibitors(ICIs).Numerous clini-cal studies have also demonstrated the substantial value of immunotherapy for resectable NSCLC patients.Nevertheless,there remain controversies surrounding the exploration of immune combination strategies,treatment-related side effects,prognostic biomarkers,as well as other issues in the neoadjuvant therapy setting.Consequently,this article presents a comprehensive overview of the recent advancements in neoadjuvant immunotherapy for resectable NSCLC,stimulating fresh perspectives and delving into its merits and challenges in clinical application.关键词
肺肿瘤/新辅助治疗/免疫检查点抑制剂/围手术期/可切除非小细胞肺癌Key words
Lung neoplasms/Neoadjuvant therapy/Immune checkpoint inhibitors/Perioperative period/Resect-able non-small cell lung cancer引用本文复制引用
齐畅,田攀文,李为民..可切除非小细胞肺癌新辅助免疫治疗研究进展[J].中国肺癌杂志,2024,27(2):138-146,9.基金项目
TThis paper was supported by the grants from National Natural Science Foundation of China(No.82072598,to Pan-wen TIAN （）
No.92159302,to Weimin LI),Science and Technology Project of Sichuan,China(No.2022ZDZX0018)(to Wei-min LI),and 1-3-5 project for disciplines of excellence,West China Hospital,Sichuan University,China(No.ZYJC21052,to Panwen TIAN （No.2022ZDZX0018）
No.ZYGD22009,to Weimin LI). 本文受国家自然科学基金项目(No.82072598,No.92159302)、四川省科技厅重大专项(No.2022ZDZX0018)和四川大学华西医院1-3-5卓越计划项目(No.ZYJC21052,No.ZYGD22009)资助 （No.82072598,No.92159302）
